Literature DB >> 30187710

Genotypic and Phenotypic Heterogeneity of LGMD1D due to DNAJB6 Mutations.

Josef Finsterer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30187710      PMCID: PMC6127425          DOI: 10.3349/ymj.2018.59.8.1008

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


× No keyword cloud information.
We read with interest the article by Kim, et al.1 concerning 3 patients with autosomal dominant limb girdle muscular dystrophy type 1D (LGMD1D) due to mutations p.Phe89Ile and p.Phe100Ile in DNAJB6. We have the following comments and concerns. If patients with LGMD1D exhibit symptoms in childhood, it is not justified to call LGMD1D a disorder only with adult onset. At least, a rare early onset and the more common late onset phenotype should be designated. Not only did Patient-2 experience muscle problems in childhood,1 but also Ruggieri, et al.2 reported a patient with childhood onset. Another LGMD1D patient with childhood onset (8 years) was described by Suarez-Cedeno, et al.3 Finally, Nam's index case had early onset at age 8 years.4 Additionally, if a patient does not complain about cardiac symptoms, this does not necessarily mean that he has no cardiac involvement. Cardiac disease can be subclinical, and thus, all patients with myopathy need to undergo prospective cardiac investigations for cardiac involvement. Cardiac involvement frequently comprises cardiomyopathy of any type (noncompaction, heart failure, or arrhythmias). Accordingly, I wonder whether there were any abnormalities detected on long-term ECG echocardiography or cardiac MRI. Typically, for most neuromuscular disorders, creatine-kinase (CK) values fluctuate. Thus, it is essential to review previous laboratory investigations to see if CK was elevated prior to diagnosis. I would be interested to know to what degrees did CK values fluctuate in the three presented patients over time. Moreover, a serum CK value of 175 U/L, as detected in Patient 1, would be abnormal in our laboratory. Provision of reference limits would be helpful. Though rare, it should be mentioned that LGMD1D may have an onset with distal muscle weakness (Table 1), as has been reported by Ruggieri, et al.2 There are also patients who generally have distally pronounced muscle weakness (Table 1).5 Distal predominance has also been reported in the three affected members of family 2 reported by Harms, et al.6 (Table 1). Two of the patients described by Kim, et al.1 had distal predominance as well (Table 1). Generally, the phenotype of LGMD1D seems to be more heterogeneous than initially assumed.
Table 1

Genetic Background of Patients with Limb Girdle Muscular Dystrophy Type 1D

ReferenceNOPEthnic originMutationPhenotypic peculiarity
Kim, et al.13Asianp.Phe89IleNone
Asianp.Phe100IleLower extremity onset, early onset
Asianp.Phe100IleBulbar symptoms, distal predominance
Jonson, et al.7>4Caucasianp.Asp98delDistal predominance
Caucasianp.Asn95IleNone
Caucasianp.Phe93LeuNone
Kojima, et al.81Asianp.Phe93LeuNone
Nam, et al.41Asianp.Phe91LeuEarly onset
Palmio, et al.93Caucasianp.Phe91IleEarly onset, respiratory failure
1Caucasianp.Phe91LeuRespiratory failure
Ruggieri, et al.22Caucasianp.Phe91Distal onset, early onset
Caucasianp.Phe100ValDistal onset, early onset
Suarez-Cedeno, et al.31Caucasianp.Phe89IleEarly onset
Couthouis, et al.104Caucasianp.Phe89IleNone
Sato, et al.112Asianp.Phe96IleNone
Asianp.Phe96LeuNone
Harms, et al.63Americanp.Pro96ArgHeal cord contracture, distal dominant
Sarparanta, et al.59Caucasiansp.Phe93LeuNone

NOP, number of patients.

Finally, we do not agree with the statement that only nine different mutations have been detected in DNAJB6 so far.1 According to Table 1, at least 10 different mutations have been reported thus far (Table 1). Overall, this interesting study could be more meaningful by distinguishing between early and late onset LGMD1D, by differentiating distal and proximal predominant affection, by prospective studies of the heart, eyes, ears, gastrointestinal tract, and kidneys to exclude multisystem involvement and by reviewing previously determined CK values.
  11 in total

1.  DNAJB6 myopathy: a vacuolar myopathy with childhood onset.

Authors:  Gerson Suarez-Cedeno; Thomas Winder; Margherita Milone
Journal:  Muscle Nerve       Date:  2014-02-24       Impact factor: 3.217

2.  A novel mutation in DNAJB6, p.(Phe91Leu), in childhood-onset LGMD1D with a severe phenotype.

Authors:  Tai-Seung Nam; Wenting Li; Suk-Hee Heo; Kyung-Hwa Lee; Anna Cho; Jin-Hong Shin; Young Ok Kim; Jong-Hee Chae; Dae-Seong Kim; Myeong-Kyu Kim; Seok-Yong Choi
Journal:  Neuromuscul Disord       Date:  2015-08-11       Impact factor: 4.296

3.  Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy.

Authors:  Matthew B Harms; R Brian Sommerville; Peggy Allred; Shaughn Bell; Duanduan Ma; Paul Cooper; Glenn Lopate; Alan Pestronk; Conrad C Weihl; Robert H Baloh
Journal:  Ann Neurol       Date:  2012-02-14       Impact factor: 10.422

4.  DNAJB6 myopathy in an Asian cohort and cytoplasmic/nuclear inclusions.

Authors:  Takatoshi Sato; Yukiko K Hayashi; Yasushi Oya; Tomoyoshi Kondo; Kazuma Sugie; Daita Kaneda; Hideki Houzen; Ichiro Yabe; Hidenao Sasaki; Satoru Noguchi; Ikuya Nonaka; Makiko Osawa; Ichizo Nishino
Journal:  Neuromuscul Disord       Date:  2013-02-06       Impact factor: 4.296

5.  Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy.

Authors:  Julien Couthouis; Alya R Raphael; Carly Siskind; Andrew R Findlay; Jason D Buenrostro; William J Greenleaf; Hannes Vogel; John W Day; Kevin M Flanigan; Aaron D Gitler
Journal:  Neuromuscul Disord       Date:  2014-02-10       Impact factor: 4.296

6.  Two Korean Families with Limb-Girdle Muscular Dystrophy Type 1D Associated with DNAJB6 Mutations.

Authors:  Kitae Kim; Hyung Jun Park; Jung Hwan Lee; Jiman Hong; Suk Won Ahn; Young Chul Choi
Journal:  Yonsei Med J       Date:  2018-07       Impact factor: 2.759

7.  Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy.

Authors:  Jaakko Sarparanta; Per Harald Jonson; Christelle Golzio; Satu Sandell; Helena Luque; Mark Screen; Kristin McDonald; Jeffrey M Stajich; Ibrahim Mahjneh; Anna Vihola; Olayinka Raheem; Sini Penttilä; Sara Lehtinen; Sanna Huovinen; Johanna Palmio; Giorgio Tasca; Enzo Ricci; Peter Hackman; Michael Hauser; Nicholas Katsanis; Bjarne Udd
Journal:  Nat Genet       Date:  2012-02-26       Impact factor: 38.330

8.  Complete loss of the DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy.

Authors:  Alessandra Ruggieri; Francesco Brancati; Simona Zanotti; Lorenzo Maggi; Maria Barbara Pasanisi; Simona Saredi; Chiara Terracciano; Carlo Antozzi; Maria Rosaria D Apice; Federica Sangiuolo; Giuseppe Novelli; Christian R Marshall; Stephen W Scherer; Lucia Morandi; Luca Federici; Roberto Massa; Marina Mora; Berge A Minassian
Journal:  Acta Neuropathol Commun       Date:  2015-07-25       Impact factor: 7.801

9.  Characteristic Posterior-dominant Lower Limb Muscle Involvement in Limb-girdle Muscular Dystrophy due to a DNAJB6 Phe93Leu Mutation.

Authors:  Yuta Kojima; Yu-Ichi Noto; Daiki Takewaki; Naoki Tokuda; Kensuke Shiga; Ai Hamano; Ikuko Mizuta; Manabu Muranishi; Takashi Kasai; Masanori Nakagawa; Toshiki Mizuno
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

10.  Novel mutations in DNAJB6 gene cause a very severe early-onset limb-girdle muscular dystrophy 1D disease.

Authors:  Johanna Palmio; Per Harald Jonson; Anni Evilä; Mari Auranen; Volker Straub; Kate Bushby; Anna Sarkozy; Sari Kiuru-Enari; Satu Sandell; Helena Pihko; Peter Hackman; Bjarne Udd
Journal:  Neuromuscul Disord       Date:  2015-07-27       Impact factor: 4.296

View more
  2 in total

1.  A novel recessive mutation affecting DNAJB6a causes myofibrillar myopathy.

Authors:  Fang-Yuan Qian; Yu-Dong Guo; Juan Zu; Jin-Hua Zhang; Yi-Ming Zheng; Idriss Ali Abdoulaye; Zhao-Hui Pan; Chun-Ming Xie; Han-Chao Gao; Zhi-Jun Zhang
Journal:  Acta Neuropathol Commun       Date:  2021-02-08       Impact factor: 7.801

2.  High-Efficiency Expression and Purification of DNAJB6b Based on the pH-Modulation of Solubility and Denaturant-Modulation of Size.

Authors:  Sara Linse
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.